Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Self-blinding citizen science to explore psychedelic microdosing
Balázs Szigeti, Laura Kärtner, Allan Blemings, et al.
eLife (2021) Vol. 10
Open Access | Times Cited: 136

Showing 1-25 of 136 citing articles:

Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials
Jacob S. Aday, Boris D. Heifets, Steven D. Pratscher, et al.
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1989-2010
Open Access | Times Cited: 146
Psychedelics and Other Psychoplastogens for Treating Mental Illness
Maxemiliano V. Vargas, Retsina Meyer, Arabo A. Avanes, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 113
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
Michiel van Elk, David B. Yaden
Neuroscience & Biobehavioral Reviews (2022) Vol. 140, pp. 104793-104793
Open Access | Times Cited: 106
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study
Federico Cavanna, Stephanie Müller, Laura Alethia de la Fuente, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 77
Therapeutic effect of psilocybin in addiction: A systematic review
Pim B. van der Meer, Juan José Fuentes, Ad A. Kaptein, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 72
The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955–2021) and recommendations for the field
Vince Polito, Paul Liknaitzky
Neuroscience & Biobehavioral Reviews (2022) Vol. 139, pp. 104706-104706
Open Access | Times Cited: 69
Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression
Balázs Szigeti, Brandon Weiss, Fernando E. Rosas, et al.
Psychological Medicine (2024) Vol. 54, Iss. 8, pp. 1717-1724
Closed Access | Times Cited: 23
Expectancy Effects in Psychedelic Trials
Balázs Szigeti, Boris D. Heifets
Biological Psychiatry Cognitive Neuroscience and Neuroimaging (2024) Vol. 9, Iss. 5, pp. 512-521
Closed Access | Times Cited: 21
Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
Rita Kočárová, Jiřı́ Horáček, Robin Carhart‐Harris
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 65
Psychedelics therapeutics: What we know, what we think, and what we need to research
David Nutt, Meg J. Spriggs, David Erritzøe
Neuropharmacology (2022) Vol. 223, pp. 109257-109257
Open Access | Times Cited: 64
Repeated low doses of LSD in healthy adults: A placebo‐controlled, dose–response study
Harriet de Wit, Hanna Molla, Anya K. Bershad, et al.
Addiction Biology (2022) Vol. 27, Iss. 2
Open Access | Times Cited: 52
The challenges ahead for psychedelic ‘medicine’
Suresh Muthukumaraswamy, Anna Forsyth, Rachael L. Sumner
Australian & New Zealand Journal of Psychiatry (2022) Vol. 56, Iss. 11, pp. 1378-1383
Closed Access | Times Cited: 48
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample
Victoria Amalie Nygart, Lis Marie Pommerencke, Eline Haijen, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 8, pp. 932-942
Open Access | Times Cited: 48
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder
Joshua D. Rosenblat, M. Ishrat Husain, Yena Lee, et al.
The Canadian Journal of Psychiatry (2022) Vol. 68, Iss. 1, pp. 5-21
Open Access | Times Cited: 38
Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial
Robin J. Murphy, Rachael L. Sumner, William J. Evans, et al.
Biological Psychiatry (2023) Vol. 94, Iss. 6, pp. 511-521
Open Access | Times Cited: 28
The costs and benefits of psychedelics on cognition and mood
Ceyda Sayalı, Frederick S. Barrett
Neuron (2023) Vol. 111, Iss. 5, pp. 614-630
Open Access | Times Cited: 24
Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry
Jacob S. Aday, Brian S. Barnett, Dan Grossman, et al.
Psychedelic Medicine (2023) Vol. 1, Iss. 3, pp. 150-165
Closed Access | Times Cited: 22
The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?
Bryan Barksdale, Manoj K. Doss, Gregory A. Fonzo, et al.
Neurotherapeutics (2024), pp. e00322-e00322
Open Access | Times Cited: 13
Microdosing Psychedelics: Current Evidence From Controlled Studies
Robin J. Murphy, Suresh Muthukumaraswamy, Harriet de Wit
Biological Psychiatry Cognitive Neuroscience and Neuroimaging (2024) Vol. 9, Iss. 5, pp. 500-511
Open Access | Times Cited: 10
Psychedelic therapy in depression and substance use disorders
Nur Damla Korkmaz, Uğur Çıkrıkçılı, Merve Akan, et al.
European Journal of Neuroscience (2024) Vol. 60, Iss. 2, pp. 4063-4077
Open Access | Times Cited: 10
Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial
David Erritzøe, Tommaso Barba, Kyle T. Greenway, et al.
EClinicalMedicine (2024), pp. 102799-102799
Open Access | Times Cited: 9
Modulation of long-term potentiation following microdoses of LSD captured by thalamo-cortical modelling in a randomised, controlled trial
Robin J. Murphy, Kate Godfrey, Alexander D. Shaw, et al.
BMC Neuroscience (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 8
Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research
Roger S. McIntyre, Angela T.H. Kwan, Rodrigo B. Mansur, et al.
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 21-32
Closed Access | Times Cited: 1
Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults
Conor H. Murray, Ilaria Tare, Claire Perry, et al.
Psychopharmacology (2021) Vol. 239, Iss. 6, pp. 1735-1747
Open Access | Times Cited: 54
Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study
Josephine Marschall, George Fejer, Pascal Lempe, et al.
Journal of Psychopharmacology (2021) Vol. 36, Iss. 1, pp. 97-113
Open Access | Times Cited: 52
Page 1 - Next Page

Scroll to top